Our study reveals that PD-1 exerted a tumor suppressive role on malignant T cells with constitutive TCR activation; PD-1 blockade therapy ameliorated the inhibitory role of PD-1 signaling on malignant T cells, thereby accelerating the progression of CTCL (Figure 5). This evidence concerns the gene PDCD1 and neoplasm.